FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
Cristina Corno(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Perego(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Gatti(Fondazione IRCCS Istituto Neurologico Carlo Besta), Emilio Ciusani(Fondazione IRCCS Istituto Neurologico Carlo Besta), Eugenio Scanziani(University of Milan), Yosef Landesman(Karyopharm Therapeutics (United States)), Serena Stamatakos(Fondazione IRCCS Istituto Nazionale dei Tumori), Simone Stucchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nives Carenini(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Lucia Minoli(University of Milan), Michelandrea De Cesare(Fondazione IRCCS Istituto Nazionale dei Tumori), Christian Argueta(Takeda (United States))
Cited by 44
Related Papers
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term<i>In vitro</i>Culture and Do Not Exhibit Telomere Maintenance Mechanisms
|Cancer Research|2007|702
miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cε
|Cancer Research|2009|363
Rational design of shepherdin, a novel anticancer agent
|Cancer Cell|2005|348
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer
|Cellular and Molecular Life Sciences|2002|274